Employees: 2
Size Drugs Made In America Acquisition II (DMII) is a United States Financials company (Financial Conglomerates) with a market value of $652M, the 2503rd largest of 3,085 United States companies the cockpit tracks. Shares closed at $10.23 on 18 Nov 2026.
Performance Over six months the shares gained 2.2%, against -1.3% for the median peer and -2.2% for the United States market (cap-weighted) — 4th highest of 19 in its peer set.
Short interest Short interest is 0.1% of the free float (30 Oct 2026).
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Revenue growth | — | — | — |
| Gross profit | $0 | $0 | $0 |
| EBITDA | -$1.37M | -$1.30M | -$151,720 |
| Net income | $17.7M | $4.19M | -$151,719 |
| Free cash flow | -$646,850 | -$1.02M | -$194,300 |
| Capital expenditure | $0 | $0 | $0 |
| Total debt | $450,000 | $0 | $250,100 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | DMII | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +0.5% | +0.2% | 8th highest of 21 |
| 6-month return | +2.2% | -1.3% | 4th highest of 19 |
| Distance from 52-week high | -1.0% | -9.5% | 3rd highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Drugs Made In America Acquisition II DMII | United States | $652M | +2% | n/a | n/a | n/a | n/a | n/a |
| Svolder SVOL-A.ST | Sweden | $667M | +42% | +1,360% | 90% | n/a | n/a | n/a |
| Bain Capital Specialty Finance BCSF | United States | $684M | -20% | -8% | 68% | n/a | n/a | n/a |
| Metalla Royalty & Streaming MTA.V | Canada | $616M | +2% | +56% | 17% | n/a | n/a | n/a |
| EQV Ventures Acquisition Corp. II EVAC | United States | $606M | +2% | n/a | n/a | n/a | n/a | n/a |
| Bain Capital GSS Investment BCSS | United States | $604M | +2% | n/a | n/a | n/a | n/a | n/a |
| Cantor Equity Partners IV CEPF | United States | $591M | 0% | n/a | n/a | n/a | n/a | n/a |
| OIO OIO | United States | $584M | -5% | -4% | -85% | n/a | n/a | n/a |
| Churchill Capital Corp XII CXII | United States | $577M | n/a | n/a | n/a | n/a | n/a | n/a |
| Senvest Capital SEC.TO | Canada | $745M | +21% | -17% | 453% | n/a | n/a | n/a |
| Luyin Investment 600784.SS | China | $563M | -28% | +4% | 5% | n/a | n/a | n/a |
| Patrizia PAT.DE | Germany | $765M | +6% | +19% | 15% | n/a | n/a | n/a |
| RMR RMR | United States | $546M | -14% | -8% | 10% | n/a | n/a | n/a |
| American Exceptionalism Acquisition AEXA | United States | $526M | -7% | n/a | n/a | n/a | n/a | n/a |
| MidCap Financial Investment MFIC | United States | $822M | -7% | -4% | 19% | n/a | n/a | n/a |
| Tangen Industrikapital TANGEN-B.ST | Sweden | $508M | n/a | +37% | 8% | n/a | n/a | n/a |
| Acceler8 Ventures AC8.L | United Kingdom | $507M | -2% | n/a | n/a | n/a | n/a | n/a |
| New America Acquisition I NWAX | United States | $500M | 0% | n/a | n/a | n/a | n/a | n/a |
| Mountain Lake Acquisition Corp. II MLAA | United States | $493M | 0% | n/a | n/a | n/a | n/a | n/a |
| Ares Acquisition Corporation III AAC | United States | $491M | -6% | n/a | n/a | n/a | n/a | n/a |
| Monex 8698.T | Japan | $884M | -14% | +4% | 14% | n/a | n/a | n/a |